vs
Side-by-side financial comparison of Orion Properties Inc. (ONL) and SOLENO THERAPEUTICS INC (SLNO). Click either name above to swap in a different company.
SOLENO THERAPEUTICS INC is the larger business by last-quarter revenue ($66.0M vs $36.3M, roughly 1.8× Orion Properties Inc.). SOLENO THERAPEUTICS INC runs the higher net margin — 39.4% vs -37.4%, a 76.8% gap on every dollar of revenue.
SOLENO THERAPEUTICS INC is a clinical-stage biopharmaceutical company specializing in developing novel therapies for rare endocrine, metabolic, and neurodevelopmental disorders. Its lead product candidate targets Prader-Willi syndrome, a rare genetic condition, with key patient markets across North America and the European Union.
ONL vs SLNO — Head-to-Head
Income Statement — Q1 FY2026 vs Q3 FY2025
| Metric | | |
|---|---|---|
| Revenue | $36.3M | $66.0M |
| Net Profit | $-13.6M | $26.0M |
| Gross Margin | — | 98.3% |
| Operating Margin | -9.3% | 33.5% |
| Net Margin | -37.4% | 39.4% |
| Revenue YoY | -4.6% | — |
| Net Profit YoY | -45.0% | 134.0% |
| EPS (diluted) | $-0.24 | $0.47 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $36.3M | — | ||
| Q4 25 | $35.2M | — | ||
| Q3 25 | $37.1M | $66.0M | ||
| Q2 25 | $37.3M | $32.7M | ||
| Q1 25 | $38.0M | — | ||
| Q4 24 | $38.4M | — | ||
| Q3 24 | $39.2M | — | ||
| Q2 24 | $40.1M | — |
| Q1 26 | $-13.6M | — | ||
| Q4 25 | $-35.8M | — | ||
| Q3 25 | $-69.0M | $26.0M | ||
| Q2 25 | $-25.1M | $-4.7M | ||
| Q1 25 | $-9.4M | — | ||
| Q4 24 | $-32.8M | — | ||
| Q3 24 | $-10.2M | — | ||
| Q2 24 | $-33.8M | — |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | 98.3% | ||
| Q2 25 | — | 97.9% | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | -9.3% | — | ||
| Q4 25 | -101.5% | — | ||
| Q3 25 | -185.8% | 33.5% | ||
| Q2 25 | -67.1% | -20.0% | ||
| Q1 25 | -24.4% | — | ||
| Q4 24 | -85.4% | — | ||
| Q3 24 | -25.9% | — | ||
| Q2 24 | -84.1% | — |
| Q1 26 | -37.4% | — | ||
| Q4 25 | -101.7% | — | ||
| Q3 25 | -186.0% | 39.4% | ||
| Q2 25 | -67.3% | -14.4% | ||
| Q1 25 | -24.6% | — | ||
| Q4 24 | -85.4% | — | ||
| Q3 24 | -26.1% | — | ||
| Q2 24 | -84.2% | — |
| Q1 26 | $-0.24 | — | ||
| Q4 25 | $-0.63 | — | ||
| Q3 25 | $-1.23 | $0.47 | ||
| Q2 25 | $-0.45 | $-0.09 | ||
| Q1 25 | $-0.17 | — | ||
| Q4 24 | $-0.59 | — | ||
| Q3 24 | $-0.18 | — | ||
| Q2 24 | $-0.60 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $10.3M | $498.9M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $608.5M | $494.8M |
| Total Assets | $1.2B | $599.9M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $10.3M | — | ||
| Q4 25 | $22.4M | — | ||
| Q3 25 | $32.6M | $498.9M | ||
| Q2 25 | $17.4M | $286.8M | ||
| Q1 25 | $9.4M | — | ||
| Q4 24 | $15.6M | — | ||
| Q3 24 | $16.6M | — | ||
| Q2 24 | $24.2M | — |
| Q1 26 | — | — | ||
| Q4 25 | $465.0M | — | ||
| Q3 25 | $483.0M | — | ||
| Q2 25 | $483.0M | — | ||
| Q1 25 | $505.0M | — | ||
| Q4 24 | $492.0M | — | ||
| Q3 24 | $485.0M | — | ||
| Q2 24 | $462.0M | — |
| Q1 26 | $608.5M | — | ||
| Q4 25 | $623.2M | — | ||
| Q3 25 | $658.8M | $494.8M | ||
| Q2 25 | $728.0M | $240.1M | ||
| Q1 25 | $753.5M | — | ||
| Q4 24 | $763.9M | — | ||
| Q3 24 | $800.9M | — | ||
| Q2 24 | $816.1M | — |
| Q1 26 | $1.2B | — | ||
| Q4 25 | $1.2B | — | ||
| Q3 25 | $1.2B | $599.9M | ||
| Q2 25 | $1.3B | $332.3M | ||
| Q1 25 | $1.3B | — | ||
| Q4 24 | $1.3B | — | ||
| Q3 24 | $1.4B | — | ||
| Q2 24 | $1.3B | — |
| Q1 26 | — | — | ||
| Q4 25 | 0.75× | — | ||
| Q3 25 | 0.73× | — | ||
| Q2 25 | 0.66× | — | ||
| Q1 25 | 0.67× | — | ||
| Q4 24 | 0.64× | — | ||
| Q3 24 | 0.61× | — | ||
| Q2 24 | 0.57× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $43.5M |
| Free Cash FlowOCF − Capex | — | $43.5M |
| FCF MarginFCF / Revenue | — | 65.8% |
| Capex IntensityCapex / Revenue | 51.4% | 0.0% |
| Cash ConversionOCF / Net Profit | — | 1.67× |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $23.6M | — | ||
| Q3 25 | $5.7M | $43.5M | ||
| Q2 25 | $11.6M | $-12.6M | ||
| Q1 25 | $-2.2M | — | ||
| Q4 24 | $54.3M | — | ||
| Q3 24 | $13.8M | — | ||
| Q2 24 | $17.0M | — |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | $43.5M | ||
| Q2 25 | — | $-12.6M | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | 65.8% | ||
| Q2 25 | — | -38.6% | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | 51.4% | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | 0.0% | ||
| Q2 25 | — | 0.0% | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | 1.67× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ONL
| Rental | $36.1M | 100% |
| Fee income from unconsolidated joint venture | $137.0K | 0% |
SLNO
Segment breakdown not available.
